Opinion|Videos|August 21, 2024
ADCs in Breast Cancer: Mechanism of Action, and Components
Medical experts discuss the distinct mechanisms and components of different antibody-drug conjugates (ADCs), including the drug, antibody, and linker, and how these components contribute to the mechanisms of ADC-related toxicities.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the different mechanisms between these antibody-drug conjugates (ADCs), as well as the different components that make up these ADCs (ie, drug, antibody, linker)?
- Please briefly comment on how the different ADC components relate to the mechanism of some of the ADC-related toxicities.
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Read a refresh of breast cancer FDA news from July, including the first approval of a pan-PI3K/mTOR inhibitor combination and a pegfilgrastim biosimilar.
Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Gedatolisib plus fulvestrant, with or without palbociclib, has been added to the NCCN guidelines for select patients with previously treated breast cancer.
Dato-DXd was approved in the European Union as monotherapy for patients with first-line metastatic TNBC who are not candidates for immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 8/2
2
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
3
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
4
Sonrotoclax Is Active in Chinese R/R MCL Cohort of the BGB-11417-201 Trial
5